. 2021 Apr 14;16(3):455–471. doi: 10.5114/wiitm.2021.105377

Table I.

Baseline characteristics of included studies

Study	Region	Period	Treat	Sample size	Sex (M/F)	Age (M ± SD)	Child-Pugh A/B	Tumor number		Tumor size	NOS	Outcome indicators
Study	Region	Period	Treat	Sample size	Sex (M/F)	Age (M ± SD)	Child-Pugh A/B	1	1–3	Tumor size	NOS	Outcome indicators
Xu ZJ, 2017 [28]	Anhui	2012–2015	LLR	30	25/5	52.8 ±9.4	29/1	65	0	≤ 3 cm	8	Operation time, blood loss, hospitalization duration, liver function, complication, local recurrence, overall survival rate, disease-free survival rate
Xu ZJ, 2017 [28]	Anhui	2012–2015	PRFA	35	27/8	57.1 ±12.7	32/3	65	0	≤ 3 cm	8
Song JX, 2016 [26]	Chongqing	2007–2013	LLR	78	70/8	48.0 ±11.1	78/0	73	83	≤ 4 cm	9	Operation time, blood loss, blood transfusion, hospitalization duration, complication, local recurrence, overall survival rate, disease-free survival rate
Song JX, 2016 [26]	Chongqing	2007–2013	PRFA	78	70/8	48.0 ±9.6	76/2	73	83	≤ 4 cm	9
Song JX, 2017 [27]	Chongqing	2012–2014	LLR	81	69/12	49.0 ±10.7	80/1	162	13	≤ 5 cm	7	Operation time, blood loss, hospitalization duration, complication, local recurrence, overall survival rate, disease-free survival rate
Song JX, 2017 [27]	Chongqing	2012–2014	PRFA	94	82/12	48.0 ±11.8	88/6	162	13	≤ 5 cm	7
He RQ, 2016 [33]	Shanxi	2009–2015	LLR	41	28/13	52.7 ±9.4	30/11	66	13	≤ 5 cm	6	Operation time, blood loss, hospitalization duration, complication, curative effect, life quality improvement
He RQ, 2016 [33]	Shanxi	2009–2015	LRFA	38	30/8	54.1 ±11.2	28/10	66	13	≤ 5 cm	6
Wang XW, 2017 [34]	Chongqing	2011–2015	LLR	61	35/26	65.4 ±15.6	46/15	105	21	≤ 3 cm	7	Complication, overall survival time, disease-free survival time, liver function
Wang XW, 2017 [34]	Chongqing	2011–2015	PRFA	65	36/29	66.5 ±16.1	47/18	105	21	≤ 3 cm	7
Cui HX, 2019 [29]	Henan	2013–2015	LLR	48	21/28	53.7 ±9.2	21/27	78	19	≤ 3 cm	7	Operation time, blood loss, hospitalization duration, complication, curative effect, overall survival rate, liver function
Cui HX, 2019 [29]	Henan	2013–2015	PRFA	49	29/20	53.3 ±9.6	21/28	78	19	≤ 3 cm	7
Song CG, 2018 [43]	Shandong	2015–2018	LLR	51	39/12	62.2 ±5.2	49/2	–	–	≤ 3 cm	6	Operation time, blood loss, hospitalization duration, curative effect, life quality improvement
Song CG, 2018 [43]	Shandong	2015–2018	PRFA	51	38/13	62.6 ±5.7	50/1	–	–	≤ 3 cm	6
Zhou SX, 2019 [30]	Zhejiang	2011–2015	LLR	45	35/10	59.5 ±10.4	31/14	66	21	≤ 5 cm	7	Hospitalization duration, complication, liver function, overall survival rate, disease-free survival rate
Zhou SX, 2019 [30]	Zhejiang	2011–2015	LRFA	42	33/9	58.3 ±10.7	27/15	66	21	≤ 5 cm	7
Zheng XW, 2019 [35]	Henan	2013–2013	LLR	31	23/8	64.2 ±2.2	–	–	–	≤ 5 cm	7	Complication, overall survival rate, disease-free survival rate
Zheng XW, 2019 [35]	Henan	2013–2013	LRFA	31	22/9	64.2 ±2.2	–	–	–	≤ 5 cm	7
Fan XK, 2018 [32]	Sichuan	2014–2016	LLR	31	25/6	58.6 ±7.2	26/5	52	17	≤ 5 cm	8	Operation time, blood loss, liver function, pain index, local recurrence, overall survival rate,
Fan XK, 2018 [32]	Sichuan	2014–2016	LRFA	38	28/10	55.7 ±6.3	29/9	52	17	≤ 5 cm	8
Ma W, 2018 [36]	Shanxi	2015–2017	LLR	60	35/25	59.7 ±9.3	–	– –	– –	≤ 5 cm	6	Operation time, hospitalization duration, complication, liver function
Ma W, 2018 [36]	Shanxi	2015–2017	PRFA	60	34/26	59.5 ±9.7	–	– –	– –	≤ 5 cm	6
Su N, 2019 [37]	Hubei	2017–2018	LLR	42	23/19	57.1 ±4.3	–	–	–	≤ 5 cm	6	Operation time, hospitalization duration, complication, liver function
Su N, 2019 [37]	Hubei	2017–2018	PRFA	42	22/20	58.6 ±4.4	–	–	–	≤ 5 cm	6
Wang YJ, 2018 [38]	Fujian	2013–2017	LLR	35	21/14	59.2 ±9.4	–	–	–	≤ 5 cm	6	Operation time, hospitalization duration, curative effect, complication, liver function
Wang YJ, 2018 [38]	Fujian	2013–2017	PRFA	35	20/15	59.5 ±9.7	–	–	–	≤ 5 cm	6
Wang X, 2018 [39]	Liaoning	2016–2017	LLR	40	28/12	66.2 ±10.8	–	–	–	≤ 3 cm	7	Operation time, hospitalization duration, complication, liver function, overall survival time, disease-free survival time
Wang X, 2018 [39]	Liaoning	2016–2017	PRFA	40	22/18	64.2 ±7.6	–	–	–	≤ 3 cm	7
Zhao J, 2018 [40]	Sichuan	2014–2016	LLR	68	38/30	55.7 ±7.6	50/18	113	21	≤ 3 cm	6	Hospitalization duration, complication, disease-free survival time
Zhao J, 2018 [40]	Sichuan	2014–2016	PRFA	66	40/26	55.4 ±7.3	49/17	113	21	≤ 3 cm	6
Zhang HY, 2019 [41]	Fujian	2012–2014	LLR	60	34/26	32.7 ±15.5	55/5	88	52	≤ 5 cm	7	Complication, local recurrence, overall survival, disease-free survival, liver function
Zhang HY, 2019 [41]	Fujian	2012–2014	PRFA	80	45/35	35.2 ±17.2	72/8	88	52	≤ 5 cm	7
Liu T, 2016 [42]	Hebei	2014–2015	LLR	106	80/26	58.9 ±1.1	83/23	157	56	≤ 5 cm	6	Curative effect, complication, quality of life
Liu T, 2016 [42]	Hebei	2014–2015	PRFA	107	98/9	58.8 ±0.3	75/32	157	56	≤ 5 cm	6	Curative effect, complication, quality of life
Lai C, 2016 [25]	Zhejiang	2006–2011	LLR	28	24/4	56.5 ±12.6	28/0	56	5	≤ 5 cm	9	Operation time, blood loss, blood transfusion, morbidity, mortality, hospital stay, local recurrence, overall survival rate, disease-free survival rate
Lai C, 2016 [25]	Zhejiang	2006–2011	PRFA	33	29/4	62.8 ±11.3	29/4	56	5	≤ 5 cm	9
Chong CC, 2019	Xianggang	2005–2015	LLR	59	46/13	57.7 ±10.5	59/0	112	6	≤ 3 cm	9	Overall survival rate, disease-free survival rate
Chong CC, 2019	Xianggang	2005–2015	RFA	59	46/13	59.3 ±11.0	58/1	112	6	≤ 3 cm	9	Overall survival rate, disease-free survival rate

LLR – laparoscopic liver resection, PRFA – percutaneous radio frequency ablation, LRFA – laparoscopic radio frequency ablation, M – male, F – female, NOS – Newcastle–Ottawa Scale, M ± SD – mean ± standard deviation.